Kintor Pharmaceutical (HKG:9939) completed the enrollment of the first subject in the phase 3 stage pivotal clinical trial of its KX-826 tincture 1% for treating male adult hair loss, specifically the androgenetic alopecia, in China.
The trial is a multi-center, randomized, double-blind, vehicle-controlled study and adopts a 2-in-1 design for the evaluation of efficacy and safety of KX-826 tincture 1.0% for the treatment of hair loss, a Monday Hong Kong bourse filing said.
The phase 3 trials are expected to enroll 666 patients in China within five months in 25 clinical research centers in the country.
The trial comprises a 24-week treatment phase followed by a month of safety observation, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.